Device Trial Radar · NCT03600168
Post-Market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Liver Surgery
Last checked: Nov 20, 2026Latest source record: Sep 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Actual
Start
Aug 2, 2018
Primary completion
Sep 4, 2019
Study completion Feb 2020
Sponsor
- Lead sponsor
- 3-D Matrix Europe SASNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.
Conditions
- Liver Resection
Interventions
PuraStat®Device
Synthetic haemostatic material
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Time-To-HaemostasisTime frame: Intraoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St James' University Hospital
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.